Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 4.4 (42 reviews) Sold : Login>>
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 22.52 Min. order: 1 piece ★★★★★ 4.5 (143 reviews) Sold : Login>>
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide US$ 22.60 Min. order: 1 piece ★★★★★ 4.3 (96 reviews) Sold : Login>>
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug US$ 28.98 Min. order: 1 piece ★★★★★ 4.9 (205 reviews) Sold : Login>>